Citi expects Anthem Bio’s revenue to grow at a 19% CAGR over financial year 2026-2028 and its Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) to grow at a 22% CAGR during the same timeframe.
Citi expects Anthem Bio’s revenue to grow at a 19% CAGR over financial year 2026-2028 and its Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) to grow at a 22% CAGR during the same timeframe.